Login / Signup

A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients.

Sarah Anne BirdCharlotte PawlynSusanna NallamilliPriya SriskandarajahMartin F KaiserKwee L YongRakesh PopatNeil RabinKevin D Boyd
Published in: British journal of haematology (2020)
Keyphrases
  • multiple myeloma
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • prognostic factors
  • patient reported outcomes